Featured News
July 21, 2025
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
June 02, 2025
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
Our Commitment to Responsibility
Corporate responsibility is inherent in our mission as an organization that actively works to support people living with complex and difficult-to-treat psychiatric and neurological disorders and to help break down barriers that prevent people from accessing care. As we do this important work, we strive to manage our business in a manner that promotes transparent governance and strong ethics; maintains extensive stakeholder engagement; and helps us grow our organization strategically, sustainably and responsibly. Our most recent Corporate Responsibility Report expounds on these efforts
Our Stories
Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communities. These stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.
Alkermes in Action 2025
Read about our 17th annual Alkermes in Action employee volunteer day.
Alkermes' Approach to New Target Discovery
Craig Hopkinson shared his thoughts on Alkermes' unique R&D approach with Pharma Tech Outlook.
HCP Perspectives: Schizophrenia and Bipolar I Disorder
Read insights from a survey of HCPs about the treatment journey for patients with serious mental illness.
Media Resources
Company Description
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.
Follow us on our social channels
